Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. | AstraZeneca’s Imfinzi has proven it can help ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) ...

AstraZeneca (LSE: AZN) has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Imfinzi be used in combination with ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

EMA committee recommends approval of AstraZeneca’s Imfinzi to treat adult patients with resectable muscle-invasive bladder cancer: Cambridge, UK Tuesday, May 27, 2025, 15:00 Hrs ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab ...